Investors seeking short-term inverse exposure often compare specialized sector products with broad-market alternatives. LABD and SPXU both deliver daily -3x leveraged inverse results but target different underlying benchmarks. LABD focuses on biotechnology equities, while SPXU tracks the S&P 500. They do not compete directly; instead, they offer distinct strategies for hedging or tactical positioning within healthcare volatility versus overall equity market declines. This comparison highlights their structural profiles for informed allocation decisions.
LABD seeks daily investment results, before fees and expenses, of 300% of the inverse of the S&P Biotechnology Select Industry Index. The fund uses swaps, futures, and other derivatives to achieve its -3x daily target and holds a limited number of positions, typically concentrated in derivatives and cash equivalents. It features an expense ratio of 1.07% and follows a passive leveraged strategy with daily rebalancing. The underlying index is equal-weighted across biotechnology companies, resulting in concentrated sector exposure primarily within healthcare. As a Direxion product, LABD emphasizes short-term tactical inverse exposure rather than buy-and-hold investing.
SPXU aims for daily investment results, before fees and expenses, of 300% of the inverse of the S&P 500 Index performance. It employs a similar derivatives-based approach with swaps and futures contracts, resetting leverage daily. The ETF maintains an expense ratio of 0.90% and operates as a passive leveraged inverse vehicle issued by ProShares. Holdings consist mainly of derivative instruments and short-term instruments to facilitate the target exposure. SPXU provides broad inverse market access across large-cap equities without sector concentration, distinguishing it as a tool for overall equity market hedging.
Biotechnology remains sensitive to regulatory approvals, clinical trial outcomes, interest rate movements, and capital availability for research and development. Broader equity markets respond to macroeconomic factors including inflation trends, Federal Reserve policy, corporate earnings cycles, and geopolitical developments. Inverse leveraged ETFs like these serve investors navigating potential sector-specific or market-wide corrections. Capital flows into defensive or hedging strategies often increase during periods of elevated volatility or uncertainty in growth-oriented segments such as biotech and large-cap technology.
In recent market cycles, LABD has exhibited higher volatility tied to biotech-specific events such as earnings reports and regulatory news, leading to amplified swings relative to broad indices. SPXU has shown more consistent inverse correlation with overall S&P 500 movements, reflecting diversified large-cap exposure. Relative positioning favors SPXU for broad market downturn expectations and LABD for targeted bets against healthcare innovation cycles. Both products experience path dependency from daily resets, underscoring their role in short-term strategies rather than multi-month holds.
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore opportunities with the AI Screener.
Based on structural efficiency, lower expense ratio, and broader diversification profile, Tickeron’s AI would currently favor SPXU for investors seeking general market inverse exposure. Its cost structure and alignment with large-cap trends provide a probabilistic edge in typical hedging scenarios compared with the higher-cost, sector-concentrated approach of LABD.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LABD moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend. In 39 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 12, 2026. You may want to consider a long position or call options on LABD as a result. In 78 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for LABD just turned positive on November 16, 2026. Looking at past instances where LABD's MACD turned positive, the stock continued to rise in 46 of 52 cases over the following month. The odds of a continued upward trend are 88%.
Following a +10.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where LABD advanced for three days, in 248 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 144 of 156 cases where LABD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for LABD crossed bearishly below the 50-day moving average on November 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
LABD broke above its upper Bollinger Band on November 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
SPXU moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend. In 38 of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 68 cases where SPXU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 16, 2026. You may want to consider a long position or call options on SPXU as a result. In 69 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for SPXU just turned positive on November 16, 2026. Looking at past instances where SPXU's MACD turned positive, the stock continued to rise in 44 of 52 cases over the following month. The odds of a continued upward trend are 85%.
The 10-day moving average for SPXU crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +9.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPXU advanced for three days, in 233 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 119 of 127 cases where SPXU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPXU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SPXU broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
| LABD | SPXU | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 78% |
| Momentum ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 88% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Advances ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| Declines ODDS (%) | 9 days ago 90% | 9 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |